4.7 Article

Aging Population and Future Burden of Pneumococcal Pneumonia in the United States

期刊

JOURNAL OF INFECTIOUS DISEASES
卷 205, 期 10, 页码 1589-1592

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jis240

关键词

-

资金

  1. CDC [TS-1363]
  2. Pfizer

向作者/读者索取更多资源

Pneumococcal pneumonia is concentrated among the elderly. Using a decision analytic model, we projected the future incidence of pneumococcal pneumonia and associated healthcare utilization and costs accounting for an aging US population. Between 2004 and 2040, as the population increases by 38%, pneumococcal pneumonia hospitalizations will increase by 96% (from 401 000 to 790 000), because population growth is fastest in older age groups experiencing the highest rates of pneumococcal disease. Absent intervention, the total cost of pneumococcal pneumonia will increase by $2.5 billion annually, and the demand for healthcare services for pneumococcal pneumonia, especially inpatient capacity, will double in coming decades.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据